“Next Phase” For CED Should Focus On Treatments That Lower Cost, MEDCAC Told
Executive Summary
The next iteration of CMS’ Medicare coverage with evidence development policy should limit application of the reimbursement tool to treatments that can lower overall health care spending, Center for Medical Technology Policy CEO Sean Tunis told the Medicare advisory committee.
You may also be interested in...
Medicare Part B: Commentary By CMS Officials
CMS officials Jonathan Blum, Louis Jacques and Tamara Jensen addressed a number of Medicare Part B-related topics of interest to the biopharmaceutical industry at the FDA/CMS Summit, including reimbursement for high-priced oncology drugs, coverage with evidence development and national coverage determinations.
Medicare CED Could Enable Expanded Use Of Expedited Drug Approvals, Policy Groups Suggest
Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.